OXSORALEN-ULTRA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Oxsoralen-ultra, and when can generic versions of Oxsoralen-ultra launch?
Oxsoralen-ultra is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in OXSORALEN-ULTRA is methoxsalen. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methoxsalen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oxsoralen-ultra
A generic version of OXSORALEN-ULTRA was approved as methoxsalen by STRIDES PHARMA on June 5th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OXSORALEN-ULTRA?
- What are the global sales for OXSORALEN-ULTRA?
- What is Average Wholesale Price for OXSORALEN-ULTRA?
Summary for OXSORALEN-ULTRA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 1 |
| What excipients (inactive ingredients) are in OXSORALEN-ULTRA? | OXSORALEN-ULTRA excipients list |
| DailyMed Link: | OXSORALEN-ULTRA at DailyMed |
Recent Clinical Trials for OXSORALEN-ULTRA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| M.D. Anderson Cancer Center | Phase 1 |
| National Cancer Institute (NCI) | Phase 1 |
US Patents and Regulatory Information for OXSORALEN-ULTRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | OXSORALEN-ULTRA | methoxsalen | CAPSULE;ORAL | 019600-001 | Oct 30, 1986 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OXSORALEN-ULTRA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch | OXSORALEN-ULTRA | methoxsalen | CAPSULE;ORAL | 019600-001 | Oct 30, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OXSORALEN-ULTRA
See the table below for patents covering OXSORALEN-ULTRA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Africa | 8102884 | ⤷ Sign Up | |
| Israel | 62762 | PHARMACEUTICAL COMPOSITIONS COMPRISING METHOXSALEN | ⤷ Sign Up |
| Japan | S572217 | METHOXSALEN COMPOSITION | ⤷ Sign Up |
| Philippines | 18681 | METHOXSALEM DOSAGE FORMS | ⤷ Sign Up |
| Ireland | 811000 | ⤷ Sign Up | |
| Australia | 7006981 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
